History of Operation Warp Speed in Timeline
Operation Warp Speed (OWS) was a US government initiative to speed up the development, production, and distribution of COVID-19 vaccines, treatments, and tests. Announced in May 2020, it was led by Moncef Slaoui and later David A. Kessler. The program ended in February 2021, with its responsibilities transferred to the White House COVID-19 Response Team.
January 2020: BioNTech Initiates "Project Lightspeed" for mRNA COVID-19 Vaccine Development
BioNTech commenced its mRNA-based COVID-19 vaccine development project, dubbed "Project Lightspeed," in mid-January 2020. This endeavor began shortly after the SARS-CoV-2 genetic sequence was publicly released.
March 27, 2020: CARES Act Passes, Providing Initial Funding for Operation Warp Speed
On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act was passed, allocating approximately $10 billion in funding for Operation Warp Speed.
April 22, 2020: Rick Bright Reassigned from BARDA Amidst Controversies
On or around April 22, 2020, Rick Bright, the director of BARDA, was reassigned following his opposition to funding certain drugs promoted by individuals with political connections. Bright argued that these drugs were potentially dangerous.
April 29, 2020: First News Report of Operation Warp Speed
On April 29, 2020, the first news report about Operation Warp Speed surfaced, marking the initial public awareness of the program.
May 15, 2020: Official Announcement of Operation Warp Speed
Operation Warp Speed was officially announced to the public on May 15, 2020, outlining its goals and objectives.
May 2020: Moncef Slaoui Appointed Head of Operation Warp Speed
In May 2020, Moncef Slaoui, a renowned vaccine researcher, was appointed as the head of Operation Warp Speed.
May 2020: US Invests in AstraZeneca Vaccine Candidate
In May 2020, the US invested US$1 billion in the University of Oxford-AstraZeneca vaccine candidate, securing 300 million doses for American use. This investment aimed to support the development and production of a promising vaccine candidate.
May 2020: Operation Warp Speed Faces Criticism Over Ambitious Vaccine Development Timeline
When Operation Warp Speed was initially announced in May 2020, its ambitious goal of developing, manufacturing, and distributing hundreds of millions of COVID-19 vaccine doses by the end of the year was met with skepticism. Critics pointed to the lengthy timelines typically associated with vaccine development, which often span years or even decades.
June 30, 2020: FDA Sets 50% Efficacy Threshold for COVID-19 Vaccine Approval
The Food and Drug Administration (FDA) announced on June 30, 2020, that any COVID-19 vaccine seeking regulatory and marketing approval would need to demonstrate at least 50% efficacy in reducing the severity of COVID-19 symptoms.
July 2020: Pfizer Joins Operation Warp Speed
Pfizer joined Operation Warp Speed in July 2020, signing a $1.95 billion contract to provide 100 million vaccine doses upon FDA approval. This partnership aimed to accelerate the development and distribution of a COVID-19 vaccine.
July 22, 2020: US Government Orders 100 Million Doses of Pfizer's COVID-19 Vaccine
On July 22, 2020, the U.S. government made a substantial commitment to securing COVID-19 vaccines by placing a conditional advance-purchase order worth $2 billion with Pfizer. This order aimed to procure 100 million doses of their vaccine candidate, with the possibility of acquiring an additional 500 million doses.
August 2020: Operation Warp Speed Selects Eight Companies for Vaccine Development Funding
In August 2020, Operation Warp Speed chose eight companies to receive a combined funding of approximately $11 billion to expedite the development and manufacturing preparations for their respective COVID-19 vaccine candidates.
August 2020: Lawsuit Filed Against Inovio for Alleged Misleading Statements
In August 2020, a class action lawsuit was filed against Inovio, alleging that the company made misleading statements about the development timeline of its vaccine candidate. This lawsuit highlighted concerns about transparency and potential market manipulation during the vaccine development race.
September 2020: Survey Reveals Vaccine Hesitancy Among Americans
A September 2020 survey indicated that half of American adults would not take a COVID-19 vaccine if available then. This hesitancy was partly due to concerns about the rapid development pace and potential risks.
September 2020: BioNTech Receives €375 Million from Germany for Vaccine Development
In a significant boost to vaccine development efforts, BioNTech secured €375 million (equivalent to US$445 million) in funding from the German government in September 2020. This substantial financial support aimed to accelerate the development and production capacity of the Pfizer-BioNTech COVID-19 vaccine.
October 2020: Operation Warp Speed Funding Increased to $18 Billion
By October 2020, the funding for Operation Warp Speed had been increased to approximately $18 billion, reflecting the program's expanding scope and the need for greater financial resources.
October 2020: Operation Warp Speed's Spending on Vaccines Outweighs Therapeutics
Data from October 2020 revealed that Operation Warp Speed had allocated a significantly larger portion of its funding to vaccines compared to therapeutics. The program had spent less than $1 billion on three monoclonal antibody treatments, while nearly $10 billion had been directed toward six vaccine candidates.
October 2020: Azar Predicts 100 Million Vaccine Doses by Year-End, Goal Later Reduced
In October 2020, then-Health and Human Services Secretary Alex Azar projected that 100 million doses of COVID-19 vaccines would be available by the end of the year. However, the Trump administration later scaled back this goal to 20 million doses. This adjustment reflected the challenges in vaccine production and distribution.
December 2, 2020: United Kingdom Grants Emergency Authorization to Pfizer-BioNTech Vaccine
The United Kingdom made a landmark decision on December 2, 2020, by becoming the first country to grant emergency use authorization to the Pfizer-BioNTech COVID-19 vaccine. This decision marked a pivotal step toward making the vaccine available to the public.
December 8, 2020: Trump Signs Executive Order on Vaccine Prioritization for the US
On December 8, 2020, President Trump signed an executive order prioritizing the sale of vaccines to the US before other countries, even if those countries had pre-existing contracts. This decision aimed to secure vaccine doses for the American population.
December 11, 2020: FDA Grants Emergency Use Authorization to Pfizer-BioNTech Vaccine in US
Following the UK's lead, the U.S. Food and Drug Administration (FDA) granted emergency use authorization to the Pfizer-BioNTech COVID-19 vaccine on December 11, 2020. This authorization paved the way for the distribution and administration of the vaccine in the United States.
December 2020: FDA Grants Emergency Use Authorization to Pfizer and Moderna Vaccines
In December 2020, the FDA issued an emergency use authorization for the Pfizer and Moderna vaccines, marking a significant milestone in the fight against COVID-19. Pfizer joined Operation Warp Speed in July 2020 and had a $1.95 billion contract to supply vaccines upon FDA approval.
December 23, 2020: Trump Administration Orders Additional 100 Million Doses from Pfizer
The Trump administration further solidified its commitment to securing COVID-19 vaccines by placing an order for an additional 100 million doses from Pfizer on December 23, 2020.
2020: Operation Warp Speed's Ambitious Goals Draw Criticism
Throughout 2020, Operation Warp Speed's ambitious objectives faced criticism due to the perceived unrealistic timeline for developing, manufacturing, and distributing hundreds of millions of COVID-19 vaccine doses by the end of the year. Critics drew upon decades of experience in viral infection vaccine development, which typically necessitates years or even decades to ensure safety and efficacy.
January 6, 2021: CDC Reports Discrepancy Between Distributed and Administered Vaccine Doses
On January 6, 2021, the Centers for Disease Control and Prevention (CDC) reported a significant discrepancy between the number of COVID-19 vaccine doses distributed and those actually administered. While 17,288,950 doses had been distributed, only 5,306,797 had been administered. This discrepancy highlighted challenges in the vaccine rollout and administration process.
January 2021: Operation Warp Speed Aims to Deliver 300 Million Vaccine Doses
According to a Department of Health and Human Services fact sheet, Operation Warp Speed's primary goal was to produce and distribute 300 million doses of safe and effective COVID-19 vaccines by January 2021.
January 2021: Operation Warp Speed Leadership Transition and Restructuring
January 2021 saw a significant shift in Operation Warp Speed's leadership and structure. Moncef Slaoui's tenure ended, and David A. Kessler briefly took over before the program transitioned to the White House COVID-19 Response Team.
January 2021: Moncef Slaoui Resigns from Operation Warp Speed
Moncef Slaoui, the head of Operation Warp Speed, resigned in early January 2021 at the request of the incoming Biden administration. Slaoui's previous ties to Moderna, a vaccine developer, had raised concerns about potential conflicts of interest.
January 2021: Biden Administration Announces Operation Warp Speed Restructure and Renaming
White House Press Secretary Jen Psaki announced in January 2021 that the Biden administration planned to restructure and rename Operation Warp Speed.
January 31, 2021: Operation Warp Speed Transitions to Biden Administration with 63.7 Million Doses Delivered
As Operation Warp Speed was being transferred to the Biden administration on January 31, 2021, a total of 63.7 million vaccine doses had been delivered out of the 200 million doses contracted from Pfizer and Moderna. This transition marked a change in leadership and approach to the vaccine rollout.
February 2021: Operation Warp Speed Transitions to White House COVID-19 Response Team
At the end of February 2021, the Biden administration transitioned Operation Warp Speed into the White House COVID-19 Response Team, reflecting a shift in leadership and approach to the pandemic.
February 2021: US Pledges to Donate Surplus Vaccines
In February 2021, following the transition of Operation Warp Speed to the White House COVID-19 Response Team, the US committed to donating surplus vaccine doses to countries with limited access, addressing concerns about global vaccine equity.
March 2021: Pfizer and Moderna Expected to Deliver 200 Million Vaccine Doses by End of March
Pfizer and Moderna were contractually obligated to provide a combined total of 200 million COVID-19 vaccine doses by the end of March 2021, as part of their agreements under Operation Warp Speed.
